Is neoadjuvant therapy a pathway to improved outcomes in localized kidney cancer?
At the 2023 SUO Annual Meeting, Grant Stewart, MD, PhD, discussed the potential of neoadjuvant therapy as a tool to help optimize the management of patients with localized kidney cancer.
2022 SUO Annual Meeting recap: Surgical and nonsurgical approaches to treating bladder cancer
“[The 2022 Huggins Medal Lecture from Harry Herr, MD] was a fascinating talk, and something that I think anyone could learn from,” says Kelly L. Stratton, MD, FACS.
Dr. Kelly Stratton discusses 2022 SUO Kidney Cancer Course
“It's very interesting to see how this continues to progress as a field,” says Kelly L. Stratton, MD FACS.
2022 SUO Annual Meeting recap: Neoadjuvant therapies in RCC
Laura Bukavina, MD, MPH, discusses a highlight from the 2022 Society of Urologic Oncology Annual Meeting.
2022 SUO Annual Meeting recap: Updates in intermediate-risk non–muscle-invasive bladder cancer
Laura Bukavina, MD, MPH, summarizes a presentation from the 2022 Society of Urologic Oncology Annual Meeting from Sarah P. Psutka, MD, MS.
Dr. Bukavina on frailty and urologic oncology
“It’s important for us to get the tools necessary to deal with patients who come with a unique set of difficulties,” says Laura Bukavina, MD, MPH.
Investigational LG-IR-NMIBC treatment UGN-102 found to have long-term durability
The median DOR among the 15 patients in the study was 24.4 months (range, 10.1 to 30.7 months).
Rollover data from OLYMPUS trial show long-term durability of LG-UTUC treatment
"Jelmyto provides an effective and durable kidney-sparing treatment option and should be considered as primary therapy for adult patients with LG-UTUC,” said Phillip Pierorazio, MD.
Latest research supporting stereotactic radiotherapy for oligometastatic renal cell carcinoma
“Stereotactic radiation can delay the initiation of systemic therapy; it can locally control oligometastatic RCC patients for as much as 2 years,” says Raquibul Hannan, MD, PhD.
Dr. Galsky explains results of pivotal adjuvant immunotherapy trials in urothelial cancer
Matthew Galsky, MD, discusses the discordant results of the pivotal phase 3 CheckMate-274 and IMvigor010 trials of adjuvant immunotherapy in urothelial cancer.
Dr. Hannan on role of stereotactic radiotherapy for kidney cancer in community setting
Raquibul Hannan, MD, PhD, describes patients with renal cell carcinoma who may be appropriate for treatment with stereotactic radiotherapy.
Obesity not linked to lower renal function following partial nephrectomy
“So I think what we can take away from this study is that just because your patient [has a higher BMI], doesn't mean that they're a poor candidate for a partial nephrectomy,” said Lachlan Shiver.
Long-term follow-up supports pembrolizumab monotherapy in BCG-unresponsive NMIBC
Pembrolizumab monotherapy continued to demonstrate durable complete responses, while rates of upstaging at the time of radical cystectomy were consistent with previous findings in the KEYNOTE-057 trial in patients with BCG-unresponsive NMIBC.
Renal functional decline after radical nephrectomy strongly associated with age
“We showed that in the oldest patient cohorts, age became an independent risk factor for development of de novo CKD after surgical intervention in patients who underwent radical nephrectomy," says Mimi Vu Nguyen.
Dr. Galsky explains the biomarker challenge with adjuvant immunotherapy in urothelial cancer
“In the adjuvant setting, we have a ‘double biomarker problem.’ Not only don’t we know which drugs work best in which patients, we actually don’t even know which patients need additional systemic treatment because many patients are already cured with surgery,” says Matthew Galsky, MD.
Neoadjuvant axitinib facilitates partial nephrectomy in ccRCC with complex renal masses
“Neoadjuvant axitinib seems to be successful in allowing some patients to undergo a partial nephrectomy who had previously been deemed unable to undergo this procedure," said Kevin Hakimi.
Expert discusses expanding role of SBRT in metastatic renal cell carcinoma
As stereotactic ablative radiation therapy enters further into the treatment space for metastatic RCC, integration of the approach is vital for physicians to focus on, according to Raquibul Hannan, MD, PhD.
Blue light cystoscopy as adjunct to white light found to decrease tumor recurrence in NMIBC
Risk of tumor recurrence in the BLC Registry group was significantly lower than in patients who received WLC alone.
Higher downstaging, improved OS observed in patients with MIBC treated with neoadjuvant pembrolizumab
OS was also found to be prolonged in the propensity score matched analysis, with a median that was not reached in the pembrolizumab arm vs 21 months in the IRC arm.
Utilization of pembrolizumab in high-risk NMIBC appears similar in real-world vs clinical trial settings
Compared with data from the KEYNOTE-057 study, the use of pembrolizumab monotherapy in the real-world setting was similar in the treatment of patients with high-risk non-muscle invasive bladder cancer.
Current state of adjuvant immunotherapy for high-risk urothelial cancer
“This is the perfect situation for the development of biomarkers to inform [patient selection for] adjuvant treatment with immune checkpoint blockade,” says Matthew Galsky, MD.
First Black recipient of prestigious SUO award discusses his path in urology
In this interview, Curtis A. Pettaway, MD, reflects on what innovations and research led to his becoming the first Black recipient of the Society of Urologic Oncology’s Huggins Award.
Renowned urologist Dr. Eila Skinner reflects on her journey in the field
"I was very early among the first women in urology, and in those days it was really going out on a limb to go into that field," said Eila C. Skinner, MD.
Dr. Morgans highlights research and advancements from SUO 2021
“Imaging advances with PSMA-directed modalities…are absolutely shifting the landscape,” says Alicia K. Morgans, MD, MPH.
Dr. Curtis Pettaway’s achievements and contributions in the field of urology
“We…had 1 of the largest African American hereditary prostate cancer projects funded through the National Cancer Institute,” says Curtis A. Pettaway, MD.
Dr. Cookson on current and future advancement in GU cancer care
“We’re [going to] have a whole new era of immune therapies and different novel ways to treat [patients], and then [utilize] combinations of these therapies,” says Michael S. Cookson, MD, MMHC, FACS.
Advice for students looking to pursue urology from the 2021 Huggins Medal recipient
“If you're thinking about urology, then what I would do is get exposure as early as possible,” says Curtis A. Pettaway, MD.
Dr. Cookson applauds this year’s SUO award recipients
“As president of SUO, it's really rewarding to be able to hand these giants these great awards,” says Michael S. Cookson, MD, MMHC, FACS.
Dr. Pettaway: 2021 recipient of SUO’s Huggins Medal
“I believe that this is, of course,…a harbinger of what is to come—those of underserved backgrounds being…featured [more] in our organizations,” says Curtis A. Pettaway, MD.
Research highlights from the 2021 SUO Annual Meeting
“The SUO has never been stronger in its ability to deliver on clinical trials,” says Michael S. Cookson, MD, MMHC, FACS.
2 Clarke Drive Cranbury, NJ 08512